Genprex Inc
(FRA:2DE0)
€
6.5
0 (0%)
Market Cap: 5.14 Mil
Enterprise Value: 2.86 Mil
PE Ratio: 0
PB Ratio: 1.56
GF Score: 31/100 Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies Transcript
Nov 06, 2020 / NTS GMT
Release Date Price:
€104
(-5.11%)
Christine Corrado
Proactive Investors Ltd. - Media
Hello, and welcome back to Proactive New York. I am Christine Corrado. With me right now is Rodney Varner, CEO at Genprex. Rodney, always great to see you. How are you doing today?
Rodney Varner
Genprex, Inc. - Chairman, President & CEO
I'm doing great, Christine. Good to see you again as well. Thanks for having me.
Questions & Answers
Christine Corrado
Proactive Investors Ltd. - Media
Of course, Rodney. A bunch of things to talk about today. Let's start with the fact that you've launched new branding for your upcoming oncology clinical trials. Can you talk about the significance of what the branding means?
Rodney Varner
Genprex, Inc. - Chairman, President & CEO
Well, the branding is very important. First of all, in order to use a brand name for a drug, one has to get approval from the FDA of that name. And there's a process for that. It's a quite a lengthy process. We did an extensive survey of brand
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot